First Global Phase 3 Trial Showing Substantial Survival Advantage Over Chemotherapy, for Patients With Progression On or After Platinum-Based Chemotherapy ...

Imdelltra is associated with improvement in overall survival compared to local standard-of-care chemotherapy among patients with small cell lung cancer.

Treatment resistance and relapse in the most common type of lung cancer can be traced to a protein called agrin, according to ...

Nearly a year after winning an accelerated approval for its DLL3-targeting small cell lung cancer (SCLC) therapy Imdelltra, ...

Lung Cancer Test Predicts Survival in Early Stages Better Than ... that patients with metastatic non-squamous non-small cell lung cancer (NSCLC) harboring specific mutations in the STK11 and ...

Eighty-five percent of diagnosed cases of lung cancer are non-small cell lung cancer (NSCLC). In this group, 5% of patients ...

First-line Rybrevant plus Lazcluze significantly extended overall survival versus Tagrisso in mutated, advanced or metastatic non-small cell lung cancer.

The team from Cancer Research UK's Manchester Institute says it has created a new in vitro model of lung squamous cell ...

The study highlights the importance of including patient self-assessment—and not just clinician assessment—when planning ...

An independent data monitoring board found that BeiGene’s ociperlimab was unlikely to significantly boost overall survival in ...

BeiGene has made the decision to end the clinical development program for ociperlimab (BGB-A1217) for the treatment of non-small cell lung cancer ...